Testing effectiveness (Phase 2)Looking for participantsNCT04239157
What this trial is testing
A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
Who this might be right for
Chronic Myelomonocytic LeukemiaMyelodysplastic SyndromeRecurrent Chronic Myelomonocytic Leukemia+3 more
M.D. Anderson Cancer Center 76